Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients.

Literature DB >> 31399525

Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients.

Junji Tanaka¹, Norina Tanaka², Yan-Hua Wang², Kenjiro Mitsuhashi², Michiko Ryuzaki², Yuki Iizuka², Aya Watanabe², Midori Ishiyama², Akihito Shinohara², Hiroshi Kazama², Shotaro Hagiwara², Kentaro Yoshinaga², Yumi Kougen³, Hirohito Kobayashi³, Hitoshi Kanno³, Masayuki Shiseki².

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Antigens, CD20
Rituximab

Year: 2019 PMID： 31399525 PMCID： PMC7109741 DOI： 10.3324/haematol.2019.226696

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

15 in total

1. Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells.

Authors: J Tanaka; J Sugita; S Shiratori; A Shigematu; S Asanuma; K Fujimoto; M Nishio; T Kondo; M Imamura
Journal: Leukemia Date: 2011-12-06 Impact factor: 11.528

2. Dasatinib enhances the expansion of CD56+CD3- NK cells from cord blood.

Authors: Junji Tanaka; Junichi Sugita; Souichi Shiratori; Akio Shigematsu; Masahiro Imamura
Journal: Blood Date: 2012-06-21 Impact factor: 22.113

3. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies.

Authors: Alice Pievani; Camilla Belussi; Christian Klein; Alessandro Rambaldi; Josée Golay; Martino Introna
Journal: Blood Date: 2010-11-03 Impact factor: 22.113

Review 4. Challenges of NK cell-based immunotherapy in the new era.

Authors: Fang Fang; Weihua Xiao; Zhigang Tian
Journal: Front Med Date: 2018-07-25 Impact factor: 4.592

5. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.

Authors: Nidale Tarek; Jean-Benoit Le Luduec; Meighan M Gallagher; Junting Zheng; Jeffrey M Venstrom; Elizabeth Chamberlain; Shakeel Modak; Glenn Heller; Bo Dupont; Nai-Kong V Cheung; Katharine C Hsu
Journal: J Clin Invest Date: 2012-08-06 Impact factor: 14.808

Review 6. Anti-CD20 monoclonal antibodies: historical and future perspectives.

Authors: Sean H Lim; Stephen A Beers; Ruth R French; Peter W M Johnson; Martin J Glennie; Mark S Cragg
Journal: Haematologica Date: 2009-09-22 Impact factor: 9.941

Review 7. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Authors: Mitchell R Smith
Journal: Oncogene Date: 2003-10-20 Impact factor: 9.867

Review 8. Targeting natural killer cells in cancer immunotherapy.

Authors: Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal: Nat Immunol Date: 2016-08-19 Impact factor: 25.606

Review 9. Current strategies exploiting NK-cell therapy to treat haematologic malignancies.

Authors: Jenna K Johnson; Jeffrey S Miller
Journal: Int J Immunogenet Date: 2018-07-16 Impact factor: 1.466

Review 10. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.

Authors: Sarah Cooley; Peter Parham; Jeffrey S Miller
Journal: Blood Date: 2018-01-22 Impact factor: 25.476

6 in total

Review 1. Immunotherapy of lymphomas.

Authors: Stephen M Ansell; Yi Lin
Journal: J Clin Invest Date: 2020-04-01 Impact factor: 14.808